FreeTender
Accepting bidsgrantUnited States

Cooperative Research Agreements Related to the World Trade Center Health Program (U01)

Issued by Centers for Disease Control and Prevention - ERA · via Grants.gov — US federal funding opportunities

Published
8 May 2026
Closes
8 Dec 2026, 23:59 UTC
Value
USD 49,500,000
Reference
RFA-OH-26-001
Location
United States
Sector
Healthcare & Pharma

At a glance

Centers for Disease Control and Prevention - ERA in United States has published a funding call in healthcare & pharma: “Cooperative Research Agreements Related to the World Trade Center Health Program (U01)”. Submissions close on 8 December 2026, 62 days from today. The stated value is USD 49,500,000. Quote reference RFA-OH-26-001 in any correspondence with the buyer. FreeTender has recorded 9 notices from this buyer since 2022, 9 of them currently open. There are 358 open healthcare & pharma notices in United States on FreeTender. Bids are submitted to the buyer through Grants.gov — US federal funding opportunities, not through FreeTender.

Details

The National Institute for Occupational Safety and Health (NIOSH) supports research projects that address: (1) physical and mental health conditions related to the September 11, 2001, terrorist attacks; (2) diagnosing conditions for which there has been diagnostic uncertainty; and (3) treating conditions for which there has been treatment uncertainty. Conditions may have emerged since the treatment program began or since the WTC Health Program was established. This announcement solicits meritorious and scientifically rigorous applications that will: 1) improve diagnosis and treatment activities of the WTC Health Program; 2) expand knowledge about health effects related to the September 11, 2001, terrorist attacks; 3) answer critical questions about WTC-related physical and mental health conditions; and 4) apply lessons learned to improve response to future disasters. Potential projects may include, but are not limited to: (a) Screening research to evaluate current methods or facilitate the development of new or improved methods to detect disorders or health conditions; (b) Diagnostic research to evaluate current methods or facilitate the development of new or improved methods to identify diseases, disorders, or conditions; (c) Treatment research to evaluate or identify improved treatment interventions or methods, or to promote development of new or novel approaches; (d) Prevention research to identify or evaluate methods and interventions that prevent or mitigate the development or recurrence of diseases or disorders; (e) Quality of life research to identify, develop, or evaluate methods or interventions that improve comfort and quality of life for individuals with chronic illness or multimorbidity; (f) Omics research to improve methods for predicting disorders by identifying and understanding relationships between genes and illness (e.g., phenotypes and biomarkers), including how genetic factors influence disease development or response to treatment; (g) Epidemiologic or clinical research to identify patterns, causes, and control of adverse health effects among the 9/11-exposed population; (h) Health services research to examine access to care, cost of care, and outcomes associated with care delivery; (i) Implementation research to evaluate how research findings are disseminated, adopted, implemented, sustained, and scaled in real-world settings; and (j) Epidemiologic research to investigate emerging conditions where preliminary data suggest, but do not confirm, a causal relationship between 9/11 exposure and the condition. Examples can be found at https://www.cdc.gov/wtc/received.html. Eligibility: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Estimated total programme funding: USD 49500000

Award range: USD 0 – 550000

Expected number of awards: 30

CFDA number(s): 93.262

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.

Context for bidders

We hold 9 notices from Centers for Disease Control and Prevention - ERA, going back to July 2022 — 9 of them still open. There are 358 open Healthcare & Pharma tenders in United States. This one closes in 62 days.

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →